Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed group of drugs. Patients receiving NSAIDs often experience abdominal discomfort, and some of them develop serious gastrointestinal complications, such as ulceration, bleeding, perforation, or obstruction. Gastrointestinal side effects of NSAIDs are mostly attributed to cyclooxygenase (COX) inhibition resulting in reduction of prostaglandin in gastric mucosa. Topical irritant effects are also contributed to their systemic effect of prostaglandin inhibition. Anti-inflammatory effects of NSAIDs are mediated by COX-2 inhibition, while COX-1 inhibition is responsible for gastric prostaglandin inhibition. Management of gastrointestinal complications of NSAIDs is costly. In order to prevent or treat the gastrointestinal complications of NSAIDs, anti-ulcer drugs can be used concomitantly. Other alternative is the application or substitution of COX-2 selective inhibitors, which spare gastric mucosal prostaglandin synthesis and do not damage the gastric mucosa. Application of COX-2 selective inhibitors as a first line treatment for arthritic disorders may not be cost-effective, if patients do not have any risk factors including advanced age, history of complicating peptic ulcer, concomitant anticoagulant and corticosteroid medication. Patients with risk factors or those developing gastrointestinal complications during the course of NSAID treatment can be treated with COX-2 selective inhibitors if necessary.
Keywords: nonsteroidal anti-inflammatory drug, cyclooxygenase, prostaglandin, gastrointestinal complications
Current Pharmaceutical Design
Title: Gastrointestinal Effects of Selective and Non-Selective Non-Steroidal Anti- Inflammatory Drugs
Volume: 11 Issue: 14
Author(s): U. S. Akarca
Affiliation:
Keywords: nonsteroidal anti-inflammatory drug, cyclooxygenase, prostaglandin, gastrointestinal complications
Abstract: Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly prescribed group of drugs. Patients receiving NSAIDs often experience abdominal discomfort, and some of them develop serious gastrointestinal complications, such as ulceration, bleeding, perforation, or obstruction. Gastrointestinal side effects of NSAIDs are mostly attributed to cyclooxygenase (COX) inhibition resulting in reduction of prostaglandin in gastric mucosa. Topical irritant effects are also contributed to their systemic effect of prostaglandin inhibition. Anti-inflammatory effects of NSAIDs are mediated by COX-2 inhibition, while COX-1 inhibition is responsible for gastric prostaglandin inhibition. Management of gastrointestinal complications of NSAIDs is costly. In order to prevent or treat the gastrointestinal complications of NSAIDs, anti-ulcer drugs can be used concomitantly. Other alternative is the application or substitution of COX-2 selective inhibitors, which spare gastric mucosal prostaglandin synthesis and do not damage the gastric mucosa. Application of COX-2 selective inhibitors as a first line treatment for arthritic disorders may not be cost-effective, if patients do not have any risk factors including advanced age, history of complicating peptic ulcer, concomitant anticoagulant and corticosteroid medication. Patients with risk factors or those developing gastrointestinal complications during the course of NSAID treatment can be treated with COX-2 selective inhibitors if necessary.
Export Options
About this article
Cite this article as:
Akarca S. U., Gastrointestinal Effects of Selective and Non-Selective Non-Steroidal Anti- Inflammatory Drugs, Current Pharmaceutical Design 2005; 11 (14) . https://dx.doi.org/10.2174/1381612053764904
DOI https://dx.doi.org/10.2174/1381612053764904 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
?Revolutionizing Cancer Treatment: Nano-Therapeutics Targeting Tumor Microenvironment?
This thematic issue explores the forefront of cancer treatment, centering on the groundbreaking potential of nano-therapeutics meticulously designed to target the tumor microenvironment. At its core, the issue aims to unravel the latest advancements in nanotechnology, showcasing innovative materials, formulations, and delivery systems that hold promise for redefining cancer therapeutics. ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Induction of Transplantation Tolerance via Regulatory T Cells
Inflammation & Allergy - Drug Targets (Discontinued) The Contribution of γδ T Cells to the Pathogenesis of EAE and MS
Current Molecular Medicine Inhibiting Protein-Protein Interactions as an Emerging Paradigm for Drug Discovery
Mini-Reviews in Medicinal Chemistry Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry Flt3 Ligand Bioactivity and Pharmacology in Neoplasia
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Identification of Interfacial Residues Involved in Hepcidin-Ferroportin Interaction
Letters in Drug Design & Discovery L-carnitine: Searching for New Therapeutic Strategy for Sepsis Management
Current Medicinal Chemistry Immunoregulatory and Effector Activities of Nitric Oxide and Reactive Nitrogen Species in Cancer
Current Medicinal Chemistry Quantitative Structure Activity Relationship Studies of Piperazinyl Phenylalanine Derivatives as VLA-4/VCAM-1 Inhibitors
Medicinal Chemistry Chelating Agents for Metal Intoxication
Current Medicinal Chemistry Germatranyl Substituted Organotin (IV) Carboxylates: Synthesis Spectroscopic Characterization and Biological Activities
Medicinal Chemistry Role of Cytokines in the Development and Maintenance of Memory T Cells During Respiratory Viral Infection
Current Pharmaceutical Design Chinese Herbal Formulas and Renal Fibrosis: An Overview
Current Pharmaceutical Design Use of Non-Selective Non-Steroidal Anti-Inflammatory Drugs in Relation to Cardiovascular Events. A Systematic Pharmacoepidemiological Review
Current Vascular Pharmacology Expression of Signaling Molecules in Progressive Multifocal Leukoencephalopathy
Current HIV Research Recent Advances in Physical Delivery Enhancement of Topical Drugs
Current Pharmaceutical Design Calcium and Vitamin D Signaling in the Epidermal Response to Wounding
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Rethinking Target Discovery in Polygenic Diseases
Current Topics in Medicinal Chemistry The Histopathology of Spondyloarthropathy
Current Molecular Medicine Biological Therapy of Hematologic Malignancies: Toward a Chemotherapy- free Era
Current Medicinal Chemistry